Drug Use Investigation for LAMICTAL
- Registration Number
- NCT01376180
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
The purpose of this study is to grasp actual status of usage of lamotrigine tablet and to collect information for using lamotrigine tablet effectively and safely as well as to grasp onset status of adverse events in pediatric subjects, geriatric subjects, pregnant women, subjects with poor renal and hepatic functions.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 3000
Inclusion Criteria
- Subjects with epilepsy having the following seizure types.
- Partial seizures (including secondary generalized seizures)
- Tonic-clonic seizures
- Generalized seizures of Lennox-Gastaut syndrome
Exclusion Criteria
- None
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Subjects prescribed lamotrigine tablet Lamotrigine Subjects with epilepsy prescribed lamotrigine tablet during study period
- Primary Outcome Measures
Name Time Method The number of adverse events in Japanese subjects with epilepsy treated with lamotrigine tablet 6 months
- Secondary Outcome Measures
Name Time Method